MIXMOVE
17.1.2023 09:31:53 CET | Business Wire | Press release
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary healthcare products.
The network offers healthcare temperature-controlled transport for parcels and 1 to 5 pallet(s) shipments throughout 25 countries. Skandi Network is composed of 7 members who are all leading healthcare carriers. The main challenge of the network is to operate cross border transport shipments that involve cross docking operations.
“Having end-to-end visibility is already a challenge with one carrier but operating multi-county and multi-carrier operations at the same time is even more challenging. As we are transporting temperature sensitive healthcare products, we must guarantee that the products are transported in alignment with the GDP regulation and that temperature is monitored and always guaranteed. It is also important that our customers can have access to that information in real time.” -Rudy Smets, CEO of Skandi Network.
For these reasons, Skandi Network teamed up with MIXMOVE to develop a unique collaborative platform - Skandi 360° - to consolidate all operational and analytical data flows for all shipments going through the network.
One view and one access to the best-in-class healthcare transport network in Europe
Skandi Network is about giving access to the best-in-class healthcare transport network in Europe, working with 7 domestic leading freight forwarders. Skandi 360° will provide a coordinated solution to the market and its different stakeholders, giving them real time access and control of the first pan-European healthcare transport network (having over 4,780 vehicles and 165 temperature-controlled depots).
Connecting to Skandi 360° will allow them to expand, and/or optimise, their own capacities in a consolidated approach.
CO2 emissions reduction
In addition, Skandi 360° will also give an opportunity to reduce the carbon footprint and the cost of ownership throughout the whole transport chain. This includes:
- Consolidation of flows,
- Optimisation of logistics networks via regional distribution centres,
- No additional passive packaging needed in the network,
- And a reduction of damages and product loss during transport thanks to temperature monitoring.
Digitalising Logistics with MIXMOVE
MIXMOVE can integrate a very large amount of information and data coming from different sources and IT systems (like TMS, telematic systems, WMS, ERP). The MIXMOVE technology turns vertical and independent data flows into a flexible and consolidated One view/One access to data, all the way up to parcel/shipment level.
MIXMOVE also makes it possible to combine transport network functionalities and collaborative platform functionalities. This enables the management of the transport network in a lean and efficient way, creating real added value for all users of Skandi Network.
MIXMOVE tailors its technology to suit specific constraints linked to the healthcare transport business, including the regulations around integrating quality management, real-time temperature follow-up (including corrective and preventive actions), and POD’s that include an end-to-end temperature curve.
“We have chosen MIXMOVE for their proven expertise in the global supply chain and their proven technology to manage complex transport network operations. They use an advanced cloud-based technology with API connectivity. The MIXMOVE solution offers a capability to connect different systems and different tools (TMS, WMS, telematic systems…) seamlessly to the platform. This is what we needed, first to allow all members to be connected, and second to allow all external stakeholders, such as logistic service providers, to plug themselves into the platform and use our network." – Rudy Smets, CEO of Skandi Network.
About Skandi Network
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary pharmaceuticals, biomedicals, APIs, temperature sensitive medical devices, diagnostics and general life products that are temperature sensitive. The network provides 2/8°C, 15/25°C and 20°C (in passive packaging) transport services and covers 25 countries thanks to the alliance of 7 leading healthcare carriers : Arra Group (Poland), BHS Logistics (Denmark, Sweden, Norway, Finland, Estonia, Latvia, Lithuania), BL Turkey Biopharma Logistics (Turkey), Eurotranspharma (France, Belgium, the Netherlands, Luxemburg, Spain, Czech Republic, Slovakia and also Germany, Austria and Slovenia via its existing local partner), Movianto (England, Scotland, Wales, Northern Ireland), PHSE (Italy), Rangel Logistics Solutions (Portugal). The aim of Skandi Network is to have members covering 36 countries by 2025. In total, the network members have more than 4,000 employees, operating in more than 4,780 temperature-controlled vehicles, 10 strategic regional consolidation platforms, 165 temperature controlled depots and transporting 14,750,000 temperature controlled shipments per year.
For more information : https://www.skandi-network.com/
About MIXMOVE
MIXMOVE provides a cloud solution supporting logistics by connecting systems, increasing profitability and reducing CO2 emissions.
For more than 10 years, MIXMOVE provides shippers, carriers and logistics service providers, the best customer experience in getting logistics transparency, predictability and resilience.
The main capabilities of the solution are focused on visibility, control and execution of transport & logistics services. Additional capabilities include optimising warehouse operations (like advanced cross-docking), order flow and fulfilment optimisation, planning automatisation, dispatching and routing optimisation.
MIXMOVE mobile applications enable digitalisation and collaboration with drivers. Trusted by customers like 3M, Volkswagen TPS, DHL, DSV, and Gebrüder Weiss, MIXMOVE has a proven track record in delivering high ROI, facilitating collaboration and helping achieve sustainability by improving resource utilisation.
For more information about MIXMOVE: www.mixmove.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005252/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
